• Transcenta posted IFRS revenue of RMB 23.6 million, more than doubled from RMB 2.7 million a year earlier.
• IFRS net loss narrowed to RMB 67.3 million from RMB 109.8 million.
• R&D expense fell 32.86% to RMB 51.5 million, while other income slid 97.83% to RMB 205,000.
• Non-IFRS adjusted net loss narrowed to RMB 65 million from RMB 99.45 million.
• Received RMB 10 million upfront and RMB 7 million milestone payments from EirGenix for HiCB licensing; aims to secure at least US$100 million funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306480), on August 28, 2026, and is solely responsible for the information contained therein.